Senolytic Treatment With Dasatinib and Quercetin Reshapes Influenza-Specific CD8 T Cell Responses During Infection in Aged, Vaccinated Mice.

Andreia N Cadar, Blake L Torrance, Sofie A Fischler, Darlene A Djaba, Zena Haddad, Dominique E Teskey, Nagaraju Marka, Kelsey A Gorgei, Erica C Lorenzo, Laura Haynes, Jenna M Bartley

Center on Aging, UConn Health, Farmington, Connecticut, USA.Center on Aging, UConn Health, Farmington, Connecticut, USA. · pubmed

Paper

Abstract

Older adults are disproportionately affected by infectious diseases like influenza (flu) due to immune declines and poor vaccine responses. Senolytics have been shown to improve various age-related conditions and positively influence infection outcomes, yet their potential to enhance vaccine responses has not yet been explored. Here, we evaluated the potential of senolytic combination Dasatinib (D) and Quercetin (Q) treatment prior to influenza vaccination to potentiate immune responses in aged mice. D + Q had minimal impact on overall vaccination and flu outcomes in vaccinated mice, including viral load and lung pathology. However, we observed altered CD8 T cell immunodominance and increased serum total PR8 (whole flu) IgG antibodies in D + Q treated vaccinated aged mice during infection. These findings reveal a new aspect of immunomodulation with senolytics.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Senolytic treatment with Dasatinib and Quercetin alters CD8 T cell responses in aged mice during influenza infection. The study explores the potential of senolytics to enhance immune responses, addressing a root cause of aging-related immune decline.

Author of this paper? Send a correction.